<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of paraneoplastic syndromes of the nervous system
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of paraneoplastic syndromes of the nervous system
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of paraneoplastic syndromes of the nervous system
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Josep Dalmau, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Myrna R Rosenfeld, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. These syndromes may affect any part of the nervous system, from cerebral cortex to neuromuscular junction and muscle  (
         <a class="graphic graphic_table graphicRef50304" href="/z/d/graphic/50304.html" rel="external">
          table 1
         </a>
         ), either damaging one area or multiple areas.
        </p>
        <p>
         This topic provides an overview of the pathogenesis, diagnosis, and treatment of paraneoplastic neurologic disorders. Individual syndromes are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15822.html" rel="external">
          "Paraneoplastic cerebellar degeneration"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15837.html" rel="external">
          "Paraneoplastic visual syndromes"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15861.html" rel="external">
          "Opsoclonus-myoclonus-ataxia syndrome"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of paraneoplastic neurologic syndromes is incompletely understood, but an immunologic basis is likely for many of them.
        </p>
        <p class="headingAnchor" id="H938104451">
         <span class="h2">
          Immunologic mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunologic factors are believed to be important because, for many of the disorders, antibody and T cell responses against nervous system antigens have been described. In such cases, the immunologic response is directed against shared antigens that are ectopically expressed by the tumor but otherwise exclusively expressed by the nervous system  (
         <a class="graphic graphic_picture graphicRef56327" href="/z/d/graphic/56327.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. Some immunologic targets reside in the testes, which normally express antigens shared with the nervous system [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         For unknown reasons, the immune system identifies these antigens as foreign and mounts an immune attack against them. Some evidence suggests that normal self-antigens are processed differently in cancer cells than in normal cells, based on the observation that the immune system can mount a T cell response to a normal protein when it is expressed in a cancer cell [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1537996321">
         <span class="h3">
          Types of neuronal antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuronal antibodies may be present in serum and/or cerebrospinal fluid (CSF) of patients with paraneoplastic neurologic syndromes. Some of these antibodies are highly specific for the presence of a cancer, and their detection serves as a marker of paraneoplasia. Other antibodies associate with specific neurologic syndromes that occur with or without cancer; these serve as markers for the neurologic syndrome without distinguishing between a paraneoplastic or nonparaneoplastic etiology.
        </p>
        <p>
         Antibodies that occur in paraneoplastic disorders can be divided in two categories depending on the location of the antigen:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intracellular neuronal antigen
         </strong>
         – Antibodies directed against intracellular neuronal proteins are referred to as classical paraneoplastic or onconeuronal antibodies. The detection of these antibodies  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ) almost always indicates the presence of an underlying tumor. These antibodies are surrogate markers of the paraneoplastic disorder, but in most of these disorders, the pathogenic mechanism is believed to be mediated by cytotoxic T cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Examples include Hu (also known as type 1 antineuronal nuclear antibody [ANNA-1]), Ri (also known as type 2 antineuronal nuclear antibody [ANNA-2]), Yo (also known as Purkinje cell cytoplasmic antibody type 1 [PCA-1]), amphiphysin, Ma2, Tr (also known as delta/notch-like epidermal growth factor-related receptor [DNER]), collapsin-responsive mediator protein 5 (CRMP5), and recoverin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuronal cell-surface or synaptic antigen
         </strong>
         – Antibodies directed against neuronal cell-surface or synaptic proteins may occur with or without a cancer or tumor association [
         <a href="#rid5">
          5
         </a>
         ]. The frequency of a tumor association varies according to the antibody. These antibodies appear to have direct pathogenic effects on the target antigens [
         <a href="#rid5">
          5
         </a>
         ]. An underlying genetic predisposition may also play a role for some of these disorders [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Examples include antibodies against the N-methyl-D-aspartate (NMDA) receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, the gamma-aminobutyric acid type A (GABA-A) and type B (GABA-B) receptors, and contactin-associated protein-like 2 (Caspr2), among others  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2427065932">
         <span class="h3">
          Pathogenic effects of antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most of the classical paraneoplastic antibodies, a pathogenic role has
         <strong>
          not
         </strong>
         been proven. However, their presence indicates the paraneoplastic nature of a neurologic disorder and, in many cases, can narrow the search for an occult tumor to a few organs  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         For many of the neuronal cell-surface protein antibody syndromes, the antibodies have been shown to be pathogenic by causing alterations in the function of the target antigen in cultured neurons or animal models of passive transfer of patients' antibodies. These alterations are usually reversible and, in animal models, are associated with reversible symptoms. Moreover, treatments that remove or deplete the antibodies often result in substantial or full recovery. Exceptions include the anti-IgLON5 syndrome, in which the antibodies cause irreversible neuronal damage. Pathogenic effects have been demonstrated for the following antibodies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         P/Q type voltage-gated calcium channel antibodies in the Lambert-Eaton myasthenic syndrome (LEMS) [
         <a href="#rid7">
          7
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acetylcholine receptor antibodies in myasthenia gravis (MG) [
         <a href="#rid8">
          8
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NMDA receptor antibodies in anti-NMDA receptor encephalitis [
         <a href="#rid9">
          9-11
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AMPA receptor antibodies in a subgroup of limbic encephalitis [
         <a href="#rid12">
          12,13
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ganglionic acetylcholine receptor antibodies in autonomic neuropathy [
         <a href="#rid14">
          14
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recoverin antibodies in carcinoma-associated retinopathy [
         <a href="#rid15">
          15
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GABA-A receptor antibodies in encephalopathy with refractory seizures [
         <a href="#rid16">
          16
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leucine-rich glioma inactivated 1 (LGI1) antibodies in a subgroup of limbic encephalitis [
         <a href="#rid17">
          17,18
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Caspr2 antibodies in patients with encephalitis and Morvan syndrome [
         <a href="#rid19">
          19
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dipeptidyl-peptidase-like protein-6 (DPPX) antibodies in a syndrome of central nervous system hyperexcitability, often associated with hyperekplexia [
         <a href="#rid20">
          20-23
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metabotropic glutamate receptor 5 (mGluR5) antibodies in encephalitis not restricted to limbic encephalitis [
         <a href="#rid24">
          24
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Autoantibodies may also play an important pathogenic role in other syndromes such as the paraneoplastic form of stiff-person syndrome (often associated with amphiphysin antibodies) [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5131.html" rel="external">
          "Stiff-person syndrome"
         </a>
         .)
        </p>
        <p>
         Previously, it had been suggested that some paraneoplastic neurologic syndromes without an identifiable tumor were a result of immune-mediated eradication of tumor cells [
         <a href="#rid26">
          26
         </a>
         ]. In addition, some reports suggested a more limited disease distribution and better outcome among patients with small cell lung cancer (SCLC) who developed immunity to paraneoplastic antigens [
         <a href="#rid27">
          27-29
         </a>
         ]. However, review of large series of patients demonstrates that the oncologic outcome of patients with antibody-associated paraneoplastic syndromes does not significantly differ from that of patients who do not have the antibodies or a paraneoplastic syndrome [
         <a href="#rid30">
          30-35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3204735717">
         <span class="h2">
          Nonimmunologic mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are also nonimmunologic mechanisms that can be involved in paraneoplastic neurologic syndromes. These include [
         <a href="#rid36">
          36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metabolic abnormalities due to tumoral secretion of hormones or cytokines (eg, hyponatremia due to antidiuretic hormone, hypercalcemia due to parathyroid hormone-related protein, or hypoglycemia due to insulin-like growth factor 2). (See
         <a class="medical medical_review" href="/z/d/html/842.html" rel="external">
          "Hypercalcemia of malignancy: Mechanisms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">
          "Hypoglycemia in adults without diabetes mellitus: Determining the etiology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Competition between the tumor and the nervous system for a substrate (eg, carcinoid tumors and tryptophan). (See
         <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">
          "Clinical features of carcinoid syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The synthesis by the tumor of immunoglobulins that react with the peripheral nervous system (eg, a distal, symmetric, and slowly progressive sensorimotor peripheral neuropathy in Waldenström macroglobulinemia) and antibodies against myelin-associated glycoprotein (MAG). (See
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paraneoplastic disorders have an incidence that varies with the neurologic syndrome and type of tumor. The more common syndromes are Lambert-Eaton myasthenic syndrome (LEMS), which affects approximately 3 percent of patients with small cell lung cancer (SCLC), and myasthenia gravis (MG), which affects 15 percent of all patients with thymoma. One or more paraneoplastic neurologic disorders are present in up to 9 percent of patients with SCLC (mostly LEMS, sensory neuronopathy, and limbic encephalitis) [
         <a href="#rid37">
          37
         </a>
         ]; for most other solid tumors, the incidence is far less than 1 percent [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Paraneoplastic peripheral neuropathies affect 5 to 15 percent of patients with a paraproteinemia-related disease including multiple myeloma, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome, multicentric Castleman disease, or lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Each of these paraproteinemias is associated with different neuropathic syndromes. (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Peripheral nerve'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Neurologic disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6662.html" rel="external">
          "POEMS syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4707.html" rel="external">
          "HHV-8/KSHV-associated multicentric Castleman disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3257698511">
         <span class="h1">
          CLINICAL SYNDROMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paraneoplastic syndromes may affect any part of the nervous system, from cerebral cortex to neuromuscular junction and muscle  (
         <a class="graphic graphic_table graphicRef50304" href="/z/d/graphic/50304.html" rel="external">
          table 1
         </a>
         ). Some syndromes affect a single area, such as the anterior horn cell in motor neuronopathy. Others affect multiple areas, as in the case of encephalomyelitis.
        </p>
        <p class="headingAnchor" id="H2919973531">
         <span class="h2">
          Central nervous system
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paraneoplastic syndromes of the central nervous system result in dysfunction of the brain and/or spinal cord. Symptoms vary depending on the areas involved. Syndromes are generally named according to the most prominent clinical signs and symptoms.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limbic encephalitis
         </strong>
         – Limbic encephalitis is characterized by acute or subacute mood and behavioral changes, short-term memory problems, focal seizures with impaired awareness, and cognitive dysfunction  (
         <a class="graphic graphic_table graphicRef111085" href="/z/d/graphic/111085.html" rel="external">
          table 3
         </a>
         ). Hypothalamic dysfunction may also occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both paraneoplastic and nonparaneoplastic presentations of limbic encephalitis can occur, and they can be clinically indistinguishable [
         <a href="#rid39">
          39
         </a>
         ]. Onconeuronal antibodies such as anti-Hu and anti-Ma2, when present, almost always associate with an underlying cancer. Associations for cell-surface or synaptic antibodies are more variable; some associate with cancer in over 50 percent of cases (eg, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA] receptor antibodies, gamma-aminobutyric acid type B [GABA-B] receptor antibodies), while others rarely do (eg, leucine-rich glioma inactivated 1 [LGI1] antibodies, contactin-associated protein-like 2 [Caspr2] antibodies). These syndromes are reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brainstem encephalitis
         </strong>
         – Brainstem encephalitis may present with a wide range of symptoms localizing to the midbrain, pons, and medulla, including extraocular movement deficits, opsoclonus, nystagmus, dysphagia, dysarthria, sensorineural deafness, trigeminal sensory loss, central hypoventilation, and vertigo. The term "rhombencephalitis" is sometimes used to denote inflammatory syndromes affecting the lower brainstem specifically. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'High-risk antibodies (&gt;70 percent cancer association)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rapidly progressive cerebellar syndrome
         </strong>
         – Some paraneoplastic disorders produce a rapidly progressive cerebellar syndrome with symptoms of limb, truncal, and gait ataxia; nystagmus; and dysarthria leading to severe disability in less than three months. Symptoms occasionally begin unilaterally or have a more insidious course. In other cases, cerebellar symptoms are just one component of a broader syndrome of encephalitis or encephalomyelitis. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'High-risk antibodies (&gt;70 percent cancer association)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Intracellular neuronal protein antibody syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Encephalomyelitis
         </strong>
         – Patients with encephalomyelitis present with symptoms that implicate multiple sites in the nervous system, including temporal-limbic regions, brainstem, cerebellum, spinal cord, dorsal root ganglia, and peripheral nervous system. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'High-risk antibodies (&gt;70 percent cancer association)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myelitis
         </strong>
         – Myelitis (or myelopathy) is characterized by progressive spastic paresis and bladder dysfunction due to involvement of the spinal cord. In paraneoplastic disorders, myelitis usually occurs in association with involvement of other areas of the nervous system (ie, encephalomyelitis). However, rare cases of isolated paraneoplastic myelopathy are observed. (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Myelopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Motor neuronopathy
         </strong>
         – Motor neuronopathy refers to dysfunction of the anterior horn cells, resulting in isolated lower motor neuron weakness and atrophy in the arms and legs. (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Subacute motor neuronopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stiff-person syndrome
         </strong>
         – Stiff-person syndrome is characterized by progressive muscle stiffness, rigidity, and spasms predominantly involving the axial muscles of the trunk and proximal muscles of the limbs. A related disorder is called progressive encephalomyelitis with rigidity and myoclonus (PERM), in which patients develop distal limb rigidity along with brainstem dysfunction, seizures, or encephalopathy. Most cases of stiff-person syndrome are not associated with a tumor or cancer, although paraneoplastic cases do occur. (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Stiff-person syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Opsoclonus-myoclonus-ataxia syndrome
         </strong>
         – Opsoclonus-myoclonus-ataxia syndrome (OMAS) is characterized by spontaneous, arrhythmic, multidirectional saccadic eye movements along with diffuse or focal body myoclonus and truncal titubation. Many patients also have ataxia and other cerebellar signs, and some have encephalopathy. In children, OMAS is symptomatic of neuroblastoma in approximately half of cases. In adults, small cell lung cancer (SCLC) or other malignancies are identified in 20 to 40 percent of cases. (See
         <a class="medical medical_review" href="/z/d/html/15861.html" rel="external">
          "Opsoclonus-myoclonus-ataxia syndrome", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3459355161">
         <span class="h2">
          Peripheral nervous system
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paraneoplastic syndromes affecting the peripheral nervous system are organized by anatomy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sensory neuronopathy
         </strong>
         – Paraneoplastic involvement of the dorsal root ganglia results in subacute sensory neuronopathy, with loss of vibratory sensation and joint position sense, sensory ataxia, and impaired pain and temperature sensation. The neuronopathy often precedes a cancer diagnosis and may progress to involve other areas of the nervous system. (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Subacute sensory neuronopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral neuropathies
         </strong>
         – A variety of peripheral neuropathies have been described as paraneoplastic syndromes, including an acute sensorimotor radiculoneuropathy that is clinically identical to Guillain-Barré syndrome, chronic sensorimotor neuropathy, neuropathies associated with lymphoproliferative disorders, autonomic neuropathy (usually in combination with other areas of nervous system involvement), and multifocal mononeuropathy due to vasculitic neuropathy. (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Peripheral nerve'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of note, recurrent gastrointestinal pseudo-obstruction (enteric neuropathy) can represent a paraneoplastic autonomic neuropathy related to myenteric plexus dysfunction, typically associated with anti-Hu antibodies. By contrast, antibodies against ganglionic acetylcholine receptor are more commonly seen in nonparaneoplastic cases. (See
         <a class="medical medical_review" href="/z/d/html/2639.html" rel="external">
          "Chronic intestinal pseudo-obstruction: Etiology, clinical manifestations, and diagnosis", section on 'Paraneoplastic'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuromuscular junction disorders
         </strong>
         – Antibodies directed against voltage-gated calcium channels in presynaptic nerve terminals result in Lambert-Eaton myasthenic syndrome (LEMS), which represents a paraneoplastic disorder in approximately 50 percent of cases. Patients present with proximal muscle weakness, autonomic dysfunction, and variable cranial nerve involvement. (See
         <a class="medical medical_review" href="/z/d/html/5174.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Myasthenia gravis (MG), a postsynaptic neuromuscular junction disorder often associated with antibodies against the acetylcholine receptor, is a paraneoplastic manifestation of a thymic tumor in approximately 10 percent of cases. Patients present with varying combinations of ptosis, diplopia, bulbar symptoms (eg, dysarthria, dysphagia, fatigable chewing), and skeletal muscle weakness. (See
         <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">
          "Clinical manifestations of myasthenia gravis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Muscle syndromes
         </strong>
         – Paraneoplastic syndromes involving muscle include dermatomyositis, acute necrotizing myopathy, and neuromyotonia (peripheral nerve hyperexcitability, or Isaacs syndrome). Nerve hyperexcitability in combination with encephalopathy and sleep disorders (Morvan syndrome) can also be seen. Clinical features of each disorder are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Muscle function'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-Caspr2-associated encephalitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2158646940">
         <span class="h2">
          Visual syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Altered vision can result from a paraneoplastic syndrome affecting the retina, the uvea, or the optic nerve.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Retinopathy
         </strong>
         – Cancer-associated retinopathy is a paraneoplastic syndrome characterized by photosensitivity, abnormal visual acuity, color vision abnormalities, scotomas, and poor night vision. A variety of antiretinal antibodies may be present in serum. A similar syndrome can occur in patients with melanoma and is also associated with a variety of antibodies that react with the bipolar cells of the retina. (See
         <a class="medical medical_review" href="/z/d/html/15837.html" rel="external">
          "Paraneoplastic visual syndromes", section on 'Cancer-associated retinopathy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15837.html" rel="external">
          "Paraneoplastic visual syndromes", section on 'Melanoma-associated retinopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uveal melanocytic proliferation
         </strong>
         – Rare patients with cancer develop bilateral diffuse uveal melanocytic proliferation causing vison loss, retinal detachment, and rapid cataract formation. Autoantibodies have not been identified, but a serum-bound protein that stimulates melanocytic proliferation in vitro has been described in some patients. (See
         <a class="medical medical_review" href="/z/d/html/15837.html" rel="external">
          "Paraneoplastic visual syndromes", section on 'Bilateral diffuse uveal melanocytic proliferation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optic neuropathy
         </strong>
         – Optic neuropathy manifests with painless visual loss and optic disc edema. Most cases of paraneoplastic optic neuropathy occur in association with additional areas of involvement, such as encephalomyelitis, retinitis, or sensorimotor neuropathy. (See
         <a class="medical medical_review" href="/z/d/html/15837.html" rel="external">
          "Paraneoplastic visual syndromes", section on 'Optic neuropathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of paraneoplastic neurologic disorders is wide and requires the reasonable exclusion of alternative causes. Many paraneoplastic syndromes develop in the early stages of cancer, and the presence of a tumor or tumor recurrence can be difficult to demonstrate. The detection of neuronal antibodies can be very helpful for diagnosis and can guide the search for a tumor. However, while some antibodies have a strong association with the presence of a cancer, other antibodies can be found in patients with or without cancer  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial diagnostic criteria developed in 2004 divided patients with suspected paraneoplastic syndromes into "definite" and "possible" categories [
         <a href="#rid40">
          40
         </a>
         ]. These criteria were updated in 2021 and now include three levels of evidence for the diagnosis of a definite, probable, or possible paraneoplastic neurologic syndrome [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The diagnostic level of certainty is based on clinical phenotype, type of antibody, presence or absence of cancer, and time of follow-up. Follow-up time is particularly relevant for those patients whose initial tumor screening is negative since the likelihood of a paraneoplastic etiology decreases as time elapses with no neoplasm identified.
        </p>
        <p>
         The criteria recognize specific clinical presentations that almost always have a paraneoplastic etiology. These syndromes are defined as "high-risk phenotypes" and are often referred to as classical paraneoplastic neurologic syndromes [
         <a href="#rid40">
          40
         </a>
         ]. Patients presenting with any of these syndromes should undergo screening for a tumor. (See
         <a class="local">
          'Search for occult malignancy'
         </a>
         below.)
        </p>
        <p>
         High-risk syndromes include (see
         <a class="local">
          'Clinical syndromes'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Encephalomyelitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limbic encephalitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapidly progressive cerebellar syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opsoclonus-myoclonus-ataxia syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sensory neuronopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal pseudo-obstruction (enteric neuropathy)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lambert-Eaton myasthenic syndrome (LEMS)
        </p>
        <p>
        </p>
        <p>
         Neurologic syndromes that can occur with or without cancer are defined as "intermediate-risk phenotypes." Recognition of these syndromes should raise concern for a paraneoplastic etiology, especially when no alternative explanation is found. A paraneoplastic etiology of an intermediate-risk phenotype should always be considered when the onset is rapidly progressive (&lt;3 months) or there are inflammatory findings in the cerebrospinal fluid (CSF) or brain/spinal magnetic resonance imaging (MRI).
        </p>
        <p>
         Intermediate-risk syndromes include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Encephalitis other than well-defined limbic encephalitis, when criteria for possible autoimmune encephalitis are fulfilled  (
         <a class="graphic graphic_table graphicRef111084" href="/z/d/graphic/111084.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis  (
         <a class="graphic graphic_table graphicRef111082" href="/z/d/graphic/111082.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brainstem encephalitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Morvan syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated myelopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stiff-person syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyradiculoneuropathies, especially axonal pattern and concurrent central nervous system involvement
        </p>
        <p>
        </p>
        <p>
         In the updated criteria, the neuronal autoantibodies are divided into three categories based on the frequency of a cancer association  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ). High-risk antibodies are those that in &gt;70 percent of cases are cancer associated. These antibodies include the classic paraneoplastic/onconeuronal antibodies described above and in the table  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Types of neuronal antibodies'
         </a>
         above). Intermediate-risk antibodies are associated with cancer in 30 to 70 percent of cases, and lower-risk antibodies are cancer associated in &lt;30 percent of cases  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         For some antibodies, such as contactin-associated protein-like 2 (Caspr2), the cancer risk level changes based on the clinical syndrome. Thus, 50 percent of patients with Caspr2 antibodies and Morvan syndrome have a tumor (usually thymoma), while less than 30 percent of patients with these antibodies and limbic encephalitis have thymoma.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Antibody screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with suspected paraneoplastic neurologic syndromes should have antibody screening performed on both serum and CSF, whenever possible. Differences in sensitivity between compartments vary by the type of antibody, as discussed below. (See
         <a class="local">
          'Interpretation'
         </a>
         below.)
        </p>
        <p>
         Clinical testing may be performed on-site in some large centers or as a send-out to a larger clinical or commercial laboratory. There are important limitations to clinical testing in certain situations, and clinicians should have a low threshold to repeat testing in a research laboratory when there is a mismatch between clinical suspicion and antibody testing results.
        </p>
        <p class="headingAnchor" id="H1477416037">
         <span class="h3">
          Testing methods
         </span>
         <span class="headingEndMark">
          —
         </span>
         The gold-standard detection method for most neuronal antibodies is rodent brain tissue immunohistochemistry/immunofluorescence accompanied by confirmatory studies using either immunoblot with recombinant proteins (for most antibodies directed toward intracellular antigens) or cell-based assays (for antibodies against cell-surface or synaptic proteins) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Despite this gold standard, very few laboratories use both techniques. Commercial kits testing multiple antibodies typically consist of immunoblots and cell-based assays. While these can be useful for initial screening, the risk of false-positive and false-negative results is higher compared with gold-standard methods. In addition, kits often include testing for antibodies of limited clinical value along with testing for validated antibodies with well-known clinical and cancer associations.
        </p>
        <p>
         When there are concerns about false-negative or false-positive results, confirmatory tissue-based testing can be requested in some clinical laboratories, or samples can be reassessed in a research laboratory.
        </p>
        <p class="headingAnchor" id="H3860367214">
         <span class="h3">
          Interpretation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Important tenets of antibody screening include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence in serum versus CSF
         </strong>
         – The existence of antibodies in serum and CSF varies across paraneoplastic disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antibodies against intracellular antigens (most classical paraneoplastic/onconeuronal antibodies) are almost always detectable in serum  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ). It is rare to find these antibodies in CSF when they are not detected in serum [
         <a href="#rid41">
          41-43
         </a>
         ]. (See
         <a class="local">
          'Types of neuronal antibodies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antibodies to cell-surface or synaptic proteins (those that associate with encephalitis with or without a cancer association) frequently occur only in CSF, or the serum may give misleading results. For these antibodies, it is particularly important to test both serum and CSF. CSF should be included in the analysis. Further guidance on antibody testing in patients with encephalitis syndromes is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Strength of neoplastic associations
         </strong>
         – For some antibodies, there is a tight association between the antibody and a characteristic syndrome, yet the antibody does not differentiate between paraneoplastic and nonparaneoplastic cases. This is the case for P/Q type voltage-gated calcium channel antibodies in patients with LEMS, acetylcholine receptor antibodies in myasthenia gravis (MG), and most encephalitis syndromes related to neuronal cell-surface and synaptic antibodies [
         <a href="#rid14">
          14,44,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other antibodies are more informative in terms of the likelihood of an underlying cancer or tumor. As an example, in the context of stiff-person syndrome, patients with glutamic acid decarboxylase (GAD) antibodies rarely have cancer, while patients with amphiphysin antibodies usually have an underlying tumor [
         <a href="#rid46">
          46,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5131.html" rel="external">
          "Stiff-person syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specificity and clinical significance
         </strong>
         – Classical paraneoplastic antibodies are sometimes found in patients with cancer but without neurologic symptoms (usually in lower titers) [
         <a href="#rid27">
          27,48,49
         </a>
         ] and in patients with neurologic disorders without an identifiable cancer [
         <a href="#rid50">
          50
         </a>
         ]. However, these antibodies  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ) rarely, if ever, occur in healthy individuals [
         <a href="#rid51">
          51-53
         </a>
         ]. The presence of these antibodies should demand a careful search for an underlying neoplasm. (See
         <a class="local">
          'Search for occult malignancy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The specificity and clinical significance of antibodies against neuronal cell-surface or synaptic proteins are reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Occurrence of multiple antibodies
         </strong>
         – Several paraneoplastic antibodies (well and/or partially characterized) may co-occur in the same patient, particularly if the underlying tumor is small cell lung cancer (SCLC) [
         <a href="#rid54">
          54,55
         </a>
         ]. In some cases, detection has clinical implications for a more treatable disorder.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, patients with SCLC and paraneoplastic cerebellar degeneration develop LEMS more frequently than expected [
         <a href="#rid56">
          56
         </a>
         ]. Since the development of both disorders is highly disabling and LEMS usually responds to treatment, all patients with SCLC who develop paraneoplastic cerebellar symptoms should be examined for LEMS. In almost all patients with LEMS, lower extremity reflexes are absent; sometimes they reappear after exercise. Another association is the development of LEMS in approximately 6 percent of patients with anti-Hu-associated paraneoplastic encephalomyelitis [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5174.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Other diagnostic tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis may be particularly difficult in patients who do not have a high-risk syndrome or when paraneoplastic antibodies are not detected. For all patients, the presumptive diagnosis of paraneoplasia requires the absence of metastatic and nonmetastatic complications that could explain the patient's symptoms, such as brain or leptomeningeal metastases and toxic effects of prior therapies.
        </p>
        <p>
         Diagnostic tests that may be helpful for some paraneoplastic syndromes include:
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Brain MRI can assist in the diagnosis of limbic encephalitis because the medial temporal lobes, the site of major pathology, often show increased signal on fluid-attenuated inversion recovery (FLAIR) images  (
         <a class="graphic graphic_diagnosticimage graphicRef111081" href="/z/d/graphic/111081.html" rel="external">
          image 1
         </a>
         ) and occasionally areas of contrast enhancement. Patients with paraneoplastic cerebellar degeneration may develop signs of atrophy detectable by MRI several months after the onset of symptoms [
         <a href="#rid56">
          56,58
         </a>
         ]; however, for most paraneoplastic syndromes, neuroimaging studies are normal or nonspecific.
        </p>
        <p>
         Positron emission tomography (PET) of the brain using fluorodeoxyglucose (FDG-PET) will occasionally identify hypermetabolism of the medial temporal lobe(s) in patients with limbic encephalopathy [
         <a href="#rid59">
          59
         </a>
         ], or of the cerebellum in patients with paraneoplastic cerebellar degeneration [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Lumbar puncture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although detection of classical paraneoplastic antibodies in CSF confirms that the disorder is paraneoplastic, in our experience these antibodies are usually present in the serum as well, except in some patients with anti-Tr antibodies [
         <a href="#rid41">
          41,43
         </a>
         ]. By contrast, CSF examination is critical in patients suspected of having antigens to neuronal cell-surface or synaptic proteins (eg, anti-NMDA receptor encephalitis) because serum testing may be negative, and antibody titers are higher in CSF than in serum [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="local">
          'Antibody screening'
         </a>
         above.)
        </p>
        <p>
         CSF examination can assist in making the diagnosis of paraneoplastic syndromes in two other ways:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The combination of negative cytology for malignant cells and the absence of meningeal enhancement on MRI can reasonably exclude leptomeningeal metastases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammatory changes (eg, pleocytosis, intrathecal synthesis of immunoglobulin G [IgG], oligoclonal bands) can support the presence of an inflammatory or immune-mediated neurologic disorder [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Electrophysiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some paraneoplastic syndromes of the peripheral nervous system are associated with characteristic electrophysiologic findings. These include LEMS, MG, neuromyotonia, and dermatomyositis. However, these findings are also present when the same neurologic syndrome is not associated with a tumor. Nevertheless, electrophysiologic findings that confirm the underlying syndrome may still be helpful by directing the search for the neoplasm to specific organs (eg, lung with LEMS and thymus with MG).
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Search for occult malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         While paraneoplastic syndromes are most often diagnosed in the setting of a known malignancy, it is common for a paraneoplastic disorder to develop before a cancer is identified. Clinical experience and the literature suggest that the large majority of tumors will be diagnosed within two years of the onset of the neurologic disorder [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The clinical syndrome and identification of certain paraneoplastic antibodies may suggest a specific underlying tumor and direct investigations  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ). In most other instances, the tumor is revealed by computed tomography (CT) of the chest, abdomen, and pelvis. Additional tests, such as mammogram, breast MRI, or ultrasound of the pelvis or testes, are ordered when suggested by the clinical syndrome and identification of certain paraneoplastic antibodies or the presence of other risk factors  (
         <a class="graphic graphic_table graphicRef135171" href="/z/d/graphic/135171.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
         Whole-body FDG-PET combined with CT is useful in demonstrating occult neoplasms or small metastatic lesions and is a reasonable alternative to sequential testing starting with CT and mammography [
         <a href="#rid63">
          63-65
         </a>
         ]. In one case series of 104 patients, sensitivity and specificity of FDG-PET were 80 and 67 percent, respectively, compared with 30 and 71 percent for CT [
         <a href="#rid66">
          66
         </a>
         ]. Results from another small study found that FDG-PET combined with CT scanning increased sensitivity and accuracy of tumor diagnosis in patients with paraneoplastic syndromes [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         A negative PET/CT scan does not rule out underlying cancer; use of other imaging modalities (eg, MRI, ultrasound) or repeating PET/CT scan after a several-month interval can be fruitful. A 2010 taskforce recommended repeat cancer screening three to six months after an initial negative evaluation, followed by screening every six months up until four years if testing remains unrevealing [
         <a href="#rid68">
          68
         </a>
         ]. In LEMS, screening for two years is sufficient. Also, if an identified cancer is not consistent with the paraneoplastic syndrome or the identified antibody, continued search for another neoplasm should be considered [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         In patients with a history of malignancy, a new-onset paraneoplastic neurologic syndrome or relapse should prompt screening for tumor recurrence. In patients with a longstanding tumor or one not matching the identified antineuronal antibody or clinical symptoms, additional screening to identify or exclude a second tumor should be performed. If a tumor with a doubtful association to the antibody and clinical phenotype is found, additional testing by a research laboratory to demonstrate that the relevant antigen is expressed by tumor cells might be useful to strengthen the paraneoplastic link [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          TREATMENT AND PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because the majority of neurologic paraneoplastic syndromes are immune mediated, two general approaches to therapy have been tried: removal of the antigen source by treatment of the underlying tumors, and suppression of the immune response with immunomodulatory therapy. The likelihood of response varies by syndrome; additional predictors of response are not well understood.
        </p>
        <p>
         In general, in the paraneoplastic disorders with antibodies against intracellular antigens (classical paraneoplastic or onconeuronal antibodies), in which the underlying pathogenic mechanism is thought to be cytotoxic T cell mediated, the response to treatment (antitumor plus immunotherapy) is less satisfactory than in those disorders associated with antibodies against neuronal cell-surface or synaptic proteins, in which the pathogenic mechanism is antibody mediated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Syndromes likely to respond to treatment
         </strong>
         – Immunomodulatory therapy is beneficial for some conditions, such as the Lambert-Eaton myasthenic syndrome (LEMS) and myasthenia gravis (MG). In these conditions, therapeutic plasma exchange or intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG; eg, 0.4 g/kg daily for five days) is usually effective in improving the neurologic status, at least in the short term. (See
         <a class="medical medical_review" href="/z/d/html/5134.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Encephalitides associated with antibodies against neuronal cell-surface antigens or synaptic proteins such as the N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), or gamma-aminobutyric acid type B (GABA-B) receptors, and leucine-rich glioma inactivated 1 (LGI1), among others, are also fairly responsive to immunomodulatory therapies. These disorders are usually treated with intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         ,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , therapeutic plasma exchange,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and/or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/140809.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Syndromes that may respond to treatment
         </strong>
         – Although most patients with paraneoplastic peripheral neuropathies do not have paraneoplastic antibodies, there is often evidence of inflammatory mechanisms likely related to an immune-mediated etiology, such as cerebrospinal fluid (CSF) pleocytosis, increased CSF proteins, or the presence of inflammatory infiltrates on nerve biopsy. For peripheral neuropathies, and particularly those with predominant demyelinating features, plasmapheresis,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         can be effective.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In cancer-associated disorders that are probably antibody mediated, such as opsoclonus-myoclonus-ataxia syndrome [
         <a href="#rid70">
          70
         </a>
         ], stiff-person syndrome [
         <a href="#rid71">
          71
         </a>
         ], and dermatomyositis [
         <a href="#rid72">
          72
         </a>
         ], the approach to treatment is usually similar to that used for syndromes associated with antibodies against cell-surface antigens. (See
         <a class="medical medical_review" href="/z/d/html/15861.html" rel="external">
          "Opsoclonus-myoclonus-ataxia syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5131.html" rel="external">
          "Stiff-person syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">
          "Initial treatment of dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Syndromes that usually do not respond to treatment
         </strong>
         – These include most of the paraneoplastic syndromes associated with classic paraneoplastic antibodies that target intracellular antigens, such as paraneoplastic cerebellar degeneration, encephalomyelitis, the subgroup of limbic encephalitis with classic paraneoplastic antibodies to intracellular antigens, myelitis, and cancer-associated retinopathy. In these patients, the treatment approach of removing the antibodies from serum (eg, therapeutic plasma exchange,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         ) usually fails; immunotherapies addressing T cell mechanisms should be considered early (eg,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , which decreases B cell antigen presentation to T cells) [
         <a href="#rid73">
          73
         </a>
         ]. Prompt control of the tumor and use of immunomodulatory therapy may stabilize symptoms or result in partial improvement [
         <a href="#rid74">
          74
         </a>
         ], but rarely to the degree seen in disorders associated with antibodies against cell-surface or synaptic proteins. (See
         <a class="medical medical_review" href="/z/d/html/140809.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Management", section on 'T cell-mediated mechanism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Across the spectrum of paraneoplastic syndromes, there is some evidence that prompt oncologic treatment and immunomodulatory therapy can be beneficial, especially if instituted during the time of symptom progression rather than after deficits have been fully established [
         <a href="#rid73">
          73,75,76
         </a>
         ]. The failure of the neurologic syndrome to respond to treatment may be due to irreversible neuronal damage that occurred before the diagnosis was made and treatment begun. Rare patients may develop a second paraneoplastic syndrome after recovering or stabilizing from the first. In one case series of eight such patients, the second paraneoplastic syndrome revealed cancer relapse in five and a second cancer in one patient [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Paraneoplastic neurologic syndromes are a heterogeneous group of disorders caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. These syndromes may affect any part of the nervous system, from cerebral cortex to neuromuscular junction and muscle  (
         <a class="graphic graphic_table graphicRef50304" href="/z/d/graphic/50304.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – Paraneoplastic neurologic syndromes are believed to result when an immunologic response is directed against shared antigens that are ectopically expressed by the tumor but otherwise predominantly expressed by the nervous system. Antibodies can be detected in the serum or cerebrospinal fluid (CSF) of many, but not all, patients with paraneoplastic syndromes. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical syndromes
         </strong>
         – Paraneoplastic syndromes may affect any part of the nervous system, from cerebral cortex to neuromuscular junction and muscle  (
         <a class="graphic graphic_table graphicRef50304" href="/z/d/graphic/50304.html" rel="external">
          table 1
         </a>
         ). Some syndromes affect a single area, such as the anterior horn cell in motor neuronopathy. Others affect multiple areas, as in the case of encephalomyelitis. (See
         <a class="local">
          'Clinical syndromes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – Patients suspected of having a paraneoplastic neurologic syndrome should be tested for paraneoplastic antibodies in both serum and CSF. Testing in both compartments is especially important for some autoimmune encephalitides associated with antibodies against neuronal cell-surface or synaptic proteins. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Important caveats include the following (see
         <a class="local">
          'Antibody screening'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Low levels of some paraneoplastic antibodies may be seen in the serum of cancer patients without paraneoplastic syndromes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Well-characterized paraneoplastic antibodies rarely, if ever, occur in healthy individuals. The presence of such antibodies should demand a careful search for an underlying neoplasm.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some but not all paraneoplastic antibodies may be associated with different neurologic syndromes, and the same neurologic syndrome may be associated with different paraneoplastic antibodies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional tests
         </strong>
         – Neuroimaging studies, lumbar puncture, and electrophysiology tests can be helpful in characterizing the neurologic syndrome. (See
         <a class="local">
          'Other diagnostic tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Detection of malignancy
         </strong>
         – The paraneoplastic syndrome may precede the diagnosis of underlying malignancy. In such cases, the clinical syndrome and identification of certain paraneoplastic antibodies may suggest a specific underlying tumor and direct investigations  (
         <a class="graphic graphic_table graphicRef135171" href="/z/d/graphic/135171.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Search for occult malignancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Two general approaches to treatment include removal of the antigen source by treatment of the underlying tumor, and suppression of the immune response. The optimal treatment and likelihood of response vary depending on the specific disorder. (See
         <a class="local">
          'Treatment and prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999; 9:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992; 141:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfeld MR, Eichen JG, Wade DF, et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage PA, Vosseller K, Kang C, et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008; 319:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Geis C, Graus F. Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev 2017; 97:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mueller SH, Färber A, Prüss H, et al. Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis. Ann Neurol 2018; 83:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang B, Newsom-Davis J, Wray D, et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30:5866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Planagumà J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015; 138:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng X, Hughes EG, Moscato EH, et al. Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 2015; 77:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohguro H, Nakazawa M. Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 2002; 514:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013; 33:18161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petit-Pedrol M, Sell J, Planagumà J, et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain 2018; 141:3144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson KR, Dalmau J, Lancaster E. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. Ann Neurol 2018; 83:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013; 73:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobin WO, Lennon VA, Komorowski L, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014; 83:1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piepgras J, Höltje M, Michel K, et al. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology 2015; 85:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hara M, Ariño H, Petit-Pedrol M, et al. DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology 2017; 88:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spatola M, Sabater L, Planagumà J, et al. Encephalitis with mGluR5 antibodies: Symptoms and antibody effects. Neurology 2018; 90:e1964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geis C, Weishaupt A, Hallermann S, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010; 133:3166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graus F, Dalmau J, Reñé R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15:2866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wirtz PW, Lang B, Graus F, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005; 164:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graus F, Keime-Guibert F, Reñe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monstad SE, Drivsholm L, Storstein A, et al. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 2004; 22:795.
          </a>
         </li>
         <li class="breakAll">
          Posner JB. Neurologic Complications of Cancer, FA Davis, 1995.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology 2015; 85:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 2000; 23:1800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology 2011; 76:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995; 58:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pozo-Rosich P, Clover L, Saiz A, et al. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solimena M, Folli F, Aparisi R, et al. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322:1555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folli F, Solimena M, Cofiell R, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drlicek M, Bianchi G, Bogliun G, et al. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 1997; 244:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Furneaux HM, Gralla RJ, et al. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol 1990; 27:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010; 257:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knudsen A, Monstad SE, Dørum A, et al. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother 2006; 55:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monstad SE, Storstein A, Dørum A, et al. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol 2006; 144:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKeon A, Lennon VA, Lachance DH, et al. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 2009; 66:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bataller L, Wade DF, Graus F, et al. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004; 62:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120 ( Pt 8):1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voltz R, Carpentier AF, Rosenfeld MR, et al. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve 1999; 22:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127:1831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 2008; 10:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi KD, Kim JS, Park SH, et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Psimaras D, Carpentier AF, Rossi C, PNS Euronetwork. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 2010; 81:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees JH, Hain SF, Johnson MR, et al. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001; 124:2223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127:2331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol 2010; 67:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel RR, Subramaniam RM, Mandrekar JN, et al. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc 2008; 83:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004; 63:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leyhe T, Schüle R, Schwärzler F, et al. Second primary tumor in anti-Ma1/2-positive paraneoplastic limbic encephalitis. J Neurooncol 2006; 78:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckley C, Vincent A. Autoimmune channelopathies. Nat Clin Pract Neurol 2005; 1:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vernino S, O'Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 2004; 6:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfeld MR, Dalmau J. Current Therapies for Paraneoplastic Neurologic Syndromes. Curr Treat Options Neurol 2003; 5:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducray F, Graus F, Vigliani MC, et al. Delayed onset of a second paraneoplastic neurological syndrome in eight patients. J Neurol Neurosurg Psychiatry 2010; 81:937.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5188 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219745" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Paraneoplastic neurologic syndromes: pathogenesis and physiopathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1415481" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11558790" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Molecular and clinical diversity in paraneoplastic immunity to Ma proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18187659" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28298428" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29572931" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6114283" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8190158" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Myasthenia gravis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18851928" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20427647" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25392198" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19338055" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25369168" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10995864" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12596918" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pathological roles of recoverin in cancer-associated retinopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24462240" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24227725" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30346486" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29244234" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23225603" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25320100" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26291285" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28258082" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : DPPX antibody-associated encephalitis: Main syndrome and antibody effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29703767" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Encephalitis with mGluR5 antibodies: Symptoms and antibody effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20884644" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8093269" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9256130" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10023900" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15904978" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11353730" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1312211" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9521251" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12111309" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10980743" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14990634" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14990634" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26109714" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11102903" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Paraneoplastic syndromes of the spinal cord, nerve, and muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34006622" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15258215" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Recommended diagnostic criteria for paraneoplastic neurological syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12552036" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16178029" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422462" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7823075" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14520669" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Voltage-gated potassium channel antibodies in limbic encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2135382" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8381208" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9120501" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2163235" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20035430" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Antibodies and neuronal autoimmune disorders of the CNS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16429314" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16542365" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19506133" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15007130" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15468074" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278623" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9883867" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15215214" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clinical analysis of anti-Ma2-associated encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18297363" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16543536" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24360484" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19324868" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cerebrospinal fluid study in paraneoplastic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11673324" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15361417" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20065123" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18674476" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15277621" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20880069" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16314942" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Second primary tumor in anti-Ma1/2-positive paraneoplastic limbic encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17006265" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16932489" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Autoimmune channelopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15692974" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Rituximab in the treatment of dermatomyositis: an open-label pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14769141" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Immunomodulatory treatment trial for paraneoplastic neurological disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16444604" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10727484" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12521564" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Current Therapies for Paraneoplastic Neurologic Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20562403" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Delayed onset of a second paraneoplastic neurological syndrome in eight patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
